Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis.

ABSTRACT:

Objectives

The aim of this study was to explore outcomes in a cohort of dcSSc patients fulfilling eligibility criteria for stem cell transplantation (SCT) studies but receiving standard immunosuppression.

Methods

From a large single-centre dcSSc cohort (n = 636), patients were identified using the published SCT trials' inclusion criteria. Patients meeting the trials' exclusion criteria were excluded.

Results

Of the 227 eligible patients, 214 met the inclusion criteria for ASTIS (Autologous Stem Cell Transplantation International Scleroderma), 82 for SCOT (Scleroderma: Cyclophosphamide Or Transplantation) and 185 for the UPSIDE (UPfront autologous haematopoietic Stem cell transplantation vs Immunosuppressive medication in early DiffusE cutaneous systemic sclerosis) tri

SUBMITTER: Spierings J 

PROVIDER: S-EPMC9071533 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature